Pangaea Oncology, S.A.

MCE PANG.MC

Pangaea Oncology, S.A. Current Liabilities for the year ending December 31, 2023: USD 7.92 M

Pangaea Oncology, S.A. Current Liabilities is USD 7.92 M for the year ending December 31, 2023, a 171.73% change year over year. Current liabilities are obligations that are expected to be settled within one year, including accounts payable, short-term debt, and other current liabilities.
  • Pangaea Oncology, S.A. Current Liabilities for the year ending December 31, 2022 was USD 2.91 M, a -19.62% change year over year.
  • Pangaea Oncology, S.A. Current Liabilities for the year ending December 31, 2021 was USD 3.63 M, a -35.18% change year over year.
  • Pangaea Oncology, S.A. Current Liabilities for the year ending December 31, 2020 was USD 5.59 M, a -0.45% change year over year.
  • Pangaea Oncology, S.A. Current Liabilities for the year ending December 31, 2019 was USD 5.62 M, a -1.00% change year over year.
Key data
Date Current Liabilities Total Non-Current Liabilities Shareholders' Equity Long-Term Debt
Market news
SV Wall Street
MCE: PANG.MC

Pangaea Oncology, S.A.

CEO Mr. Javier Rivela-Rodriguez C.F.A., M.B.A.
IPO Date Sept. 19, 2017
Location Spain
Headquarters Sabino Arana, 5-19
Employees 149
Sector Healthcare
Industries
Biotechnology Clinical Trials Pharmaceuticals
Description

Pangaea Oncology, S.A., a medical services company, provides a range of services to cancer patients in Spain and the rest of European Union countries. The company offers molecular diagnostics, such as mutation analysis in tumor tissue and blood, gene amplification and translocation testing, immunohistochemistry, and gene expression; clinical trials; in vitro drug profiling, including MTT proliferation assays, western blotting, colony formation, migration and invasion assays, and gene silencing; and Dx platform, which performs companion diagnostic platform validation, validation against commercially available platforms, and Ad-hoc R+D for diagnostics companies. It also provides biomarker discovery to identify novel targets for targeted therapies in pre-clinical development. Pangaea Oncology, S.A. was founded in 2006 and is based in Barcelona, Spain.

StockViz Staff

February 7, 2025

Any question? Send us an email